Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828139 · ClinicalTrials.gov registry record · Phase 2
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT00828139: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00828139 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 189 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00828139, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying topotecan to see how well it works when given with or without aflibercept in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combinations of biological substances in aflibercept may be able to carry tumor-killing substances directly to small cell lung cancer cells. Aflibercept may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. It is not yet known whether topotecan is more effective with or without aflibercept in treating patients with small cell lung cancer.
Interventions
- DRUG topotecan hydrochloride
- BIOLOGICAL ziv-aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00828139
The ClinicalTrials.gov registry entry for NCT00828139 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan hydrochloride is the first listed.
NCT00828139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00828139 about?
NCT00828139 is a clinical study titled "S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer". This randomized phase II trial is studying topotecan to see how well it works when given with or without aflibercept in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by ki...
What is the current status of trial NCT00828139?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2009-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00828139?
The interventions under investigation include: topotecan hydrochloride (DRUG), ziv-aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00828139?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.